Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics

Early Intervention in Psychiatry

Volumn 8, Issue 3, 2014, Pages 276-280

  O'Donoghue, Brian ^a   Schäfer, Miriam R ^b,c   Becker, Jana ^c   Papageorgiou, Konstantinos ^c   Amminger, G Paul ^b,c  

^a Early Psychosis Prevention and Intervention Centre Orygen Youth Health   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotic; Early onset schizophrenia; Medication side effect; Metabolic syndrome; Psychosis

Indexed keywords

CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BODY MASS; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; EARLY ONSET SCHIZOPHRENIA; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; AUSTRALIA; BLOOD; CHEMICALLY INDUCED; COMPLICATION; METABOLIC SYNDROME X; METABOLISM; ONSET AGE;

ADOLESCENT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CHOLESTEROL; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; RISPERIDONE; SCHIZOPHRENIA; TRIGLYCERIDES; VICTORIA;

EID: 84904762050     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12083     Document Type: Article

References (18)

1. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121.
2. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26: 144-158.
3. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773.
4. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771-791.
5. McGorry PD, Purcell R, Goldstone S, Amminger GP. Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Curr Opin Psychiatry 2011; 24: 301-306.
6. Sikich L, Frazier JA, McClellan J etal. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165: 1420-1431.
7. Guo SS, Chumlea WC. Tracking of body mass index in children in relation to overweight in adulthood. Am J Clin Nutr 1999; 70: 145S-148.
8. Vourdas A, Pipe R, Corrigall R, Frangou S. Increased developmental deviance and premorbid dysfunction in early onset schizophrenia. Schizophr Res 2003; 62: 13-22.
9. Zimmet P, Alberti KG, Kaufman F etal. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes 2007; 8: 299-306.
10. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. J Pediatr 2003; 142: 368-372.
11. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243.
12. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.
13. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-667.
14. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011; 25: 1035-1059.
15. Thompson A, Hetrick SE, Varez-Jimenez M etal. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Aust N Z J Psychiatry 2011; 45: 740-748.
16. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL etal. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1253-1260.
17. Curtis J, Newall HD, Samaras K. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry 2012; 6: 347-353.
18. Amminger GP, Henry LP, Harrigan SM etal. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 2011; 131: 112-119.